Learn More
Invitrogen™ RUNX1 Recombinant Rat Monoclonal Antibody (RXDMC), Alexa Fluor™ Plus 488
Description
Alexa Fluor™ Plus recombinant antibodies are conjugated using new, proprietary dye chemistry so you can generate stunning data. Alexa Fluor™ Plus antibodies represent an advancement in fluorescent conjugate technology. Alexa Fluor™ Plus antibodies provide brighter signal compared to leading Alexa Fluor™ antibodies, providing you with better signal-to-noise for your critical experiments. These antibodies show better specificity and lot-to-lot consistency as these are recombinant antibodies, generated by cloning specific genes for the desired antibodies into an expression vector and expressed in vitro. Using conjugate solutions: Centrifuge the protein conjugate solution briefly in a microcentrifuge before use; add only the supernatant to the experiment. This step will help eliminate any protein aggregates that may have formed during storage, thereby reducing nonspecific background staining. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest. Excitation: 494 nm; Emission: 519 nm; Laser: Blue Laser Filtration: 0.2 μm post-manufacturing filtered.
Specifications
Specifications
| Antigen | RUNX1 |
| Applications | Flow Cytometry |
| Classification | Recombinant Monoclonal |
| Clone | RXDMC |
| Concentration | 1 mg/mL |
| Conjugate | Alexa Fluor Plus 488 |
| Formulation | Proprietary buffer with 0.008% Bromonitrodioxane, 0.008% Methylisothiazolone; pH 6.3-7.3 |
| Gene | RUNX1 |
| Gene Accession No. | Q01196 |
| Gene Alias | acute myeloid leukemia 1 protein; Acute myeloid leukemia 2 protein; acute myeloid leukemia 3 protein; acute myeloid leukemia gene 2; AML1; AML-1; aml1 oncogene; AML1-EVI-1; AML1-EVI-1 fusion protein; AML2; AML3; AMLCR1; CBF2alpha; CBFA1; CBFA2; CBFA3; CBF-alpha 2; CBF-alpha-1; CBF-alpha-2; CBF-alpha-3; CCD; CCD1; CLCD; core binding factor alpha 2; core-binding factor runt domain alpha subunit 2 (acute myeloid leukemia 1 oncogene); Core-binding factor subunit alpha-1; Core-binding factor subunit alpha-2; core-binding factor subunit alpha-3; core-binding factor, runt domain, alpha subunit 1; core-binding factor, runt domain, alpha subunit 2; core-binding factor, runt domain, alpha subunit 3; EVI-1; Oncogene AML-1; oncogene AML-2; Oncogene AML-3; OSF2; OSF-2; osteoblast-specific transcription factor 2; OTTHUMP00000108697; OTTHUMP00000108700; OTTHUMP00000108702; PEA2 alpha C; PEA2aA; PEA2-alpha A; PEA2-alpha B; PEA2-alpha C; PEBP2 alpha C; PEBP2A; Pebp2a2; PEBP2A3; PEBP2aA; PEBP2aB; PEBP2aC; PEBP2alpha; PEBP2-alpha A; PEBP2-alpha B; PEBP2-alpha C; Pebpa2b; polyomavirus enhancer-binding protein 2 alpha A subunit; Polyomavirus enhancer-binding protein 2 alpha B subunit; polyomavirus enhancer-binding protein 2 alpha C subunit; RUN1; runt domain, alpha subunit 2; runt related transcription factor 1; runt related transcription factor 2; runt related transcription factor 3; runt-related transcription factor 1; Runt-related transcription factor 2; runt-related transcription factor 3; Runx1; RUNX1/ZNF687 fusion; RUNX2; RUNX3; SL3/AKV core-binding factor alpha A subunit; SL3/AKV core-binding factor alpha B subunit; SL3/AKV core-binding factor alpha C subunit; SL3-3 enhancer factor 1 alpha A subunit; SL3-3 enhancer factor 1 alpha B subunit; SL3-3 enhancer factor 1 alpha C subunit; transcription factor; transcription factor AML2 |
| Show More |
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.